Difficulty: Medium
Average Score: 70%
Practice
Tumor lysis syndrome is a common complication during treatment of pediatric malignancies. Which malignancy is more likely to manifest such complication?
Correct answer
D
Rationale
In pediatric oncology, tumor lysis syndrome (TLS) is a serious complication that can occur due to the rapid breakdown of cancer cells leading to metabolic imbalances. Burkitt lymphoma is more likely to manifest TLS because it is a highly proliferative malignancy with a high tumor burden, resulting in a significant release of intracellular contents upon treatment initiation.
Acute myelogenous leukemia (AML) is a rapidly dividing cancer, but it usually presents with a lower tumor burden compared to Burkitt lymphoma. Nephroblastoma (Wilms tumor) and neuroblastoma are also childhood malignancies but are not typically associated with the high tumor burden that predisposes to TLS.
Educationally, understanding the risk factors associated with TLS in pediatric oncology is crucial for nurses and healthcare providers caring for these patients. Recognizing the malignancies that are more likely to manifest TLS can help in early identification, monitoring, and prevention of this potentially life-threatening complication during cancer treatment. It also emphasizes the importance of close monitoring and prompt intervention to prevent TLS-related complications and improve patient outcomes.
Acute myelogenous leukemia (AML) is a rapidly dividing cancer, but it usually presents with a lower tumor burden compared to Burkitt lymphoma. Nephroblastoma (Wilms tumor) and neuroblastoma are also childhood malignancies but are not typically associated with the high tumor burden that predisposes to TLS.
Educationally, understanding the risk factors associated with TLS in pediatric oncology is crucial for nurses and healthcare providers caring for these patients. Recognizing the malignancies that are more likely to manifest TLS can help in early identification, monitoring, and prevention of this potentially life-threatening complication during cancer treatment. It also emphasizes the importance of close monitoring and prompt intervention to prevent TLS-related complications and improve patient outcomes.